INSM News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

IN

Mkt Cap

$21.02B

Volume

2.09M

Next Earnings

October 29th

Loading chart

IN

INSMInsmed, Inc.

INSM

Pay with—

Available Balance0.00

IN

Mkt Cap

$21.02B

Volume

2.09M

Next Earnings

October 29th

Chart Financials Earnings News About Insider Filings

INSM Stock Slides on CFO Exit, Reiterates '26 Sales ViewInsmed's stock fell nearly 7% following the announcement that CFO Sara Bonstein will step down effective October 30 after nearly seven years in the role. Despite the leadership transition, the company reaffirmed its 2026 revenue guidance, expecting Brinsupri revenues of $1.25-$1.40 billion and Arikayce sales of $450-$470 million. The decline reflects investor uncertainty about the unexpected departure of a key executive during a critical growth phase.Zacks Investment Research · Oct 6, 2026

Liquidia Stock Plunges 57% on UTHR Patent Litigation SetbackA U.S. District Court ruled that two claims of United Therapeutics' '327 patent are valid and infringed by Liquidia's lead drug Yutrepia, causing a 57% decline in LQDA stock. Liquidia plans to remove the PH-ILD indication from Yutrepia's label to potentially preserve the drug's availability, narrowing its addressable market. The ruling creates significant uncertainty around Yutrepia's commercial outlook, with United Therapeutics seeking injunctive relief while Liquidia pursues appeals.Zacks Investment Research · Oct 1, 2026

FDA Accepts Insmed's Filing Seeking Label Expansion for ArikayceInsmed announced FDA acceptance of a regulatory filing for Arikayce label expansion to treat newly diagnosed MAC lung disease patients. The FDA granted priority review with a decision expected by January 28, 2027. Arikayce sales grew 7% to $214.4 million in H1 2026, with full-year expectations of $450-470 million. The label expansion could significantly increase the addressable market from 30,000 to over 200,000 patients.Zacks Investment Research · Sep 22, 2026

LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?Liquidia's lead drug Yutrepia has gained significant market traction with over 5,000 patients started on therapy as of July 2026, but the stock has underperformed due to heavy reliance on a single product, ongoing patent litigation with United Therapeutics, competitive pressures, and rising R&D costs. Analysts recommend avoiding the stock due to an unfavorable risk-reward profile.Zacks Investment Research · Sep 11, 2026

Nontuberculous Mycobacterial Infections Market to Showcase Growth at a CAGR of 12.6% During the Forecast Period (2026–2036), Driven by Rising Disease Burden and Emerging Therapies | DelveInsightThe nontuberculous mycobacterial (NTM) infections market is projected to grow at a CAGR of 12.6% from 2026-2036, valued at USD 750 million in 2025. Growth is driven by rising disease prevalence, improved diagnostics, and emerging therapies including Omadacycline (NUZYRA), MRX-5, Epetraborole, and RHB-204. The US represents the largest market with approximately 400,000 diagnosed NTM cases across the 7MM countries.GlobeNewswire Inc. · Aug 31, 2026

Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?Liquidia Corporation's lead drug Yutrepia generated $300.3 million in first-half 2026 sales, driving the company's fourth consecutive profitable quarter. However, the pulmonary arterial hypertension (PAH) market faces intense competition from established therapies and pipeline candidates from United Therapeutics and Insmed. Liquidia plans to expand Yutrepia into additional indications including COPD, IPF, PPF, and Raynaud's phenomenon to sustain long-term growth.Zacks Investment Research · Aug 31, 2026

Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?Liquidia (LQDA) and Insmed (INSM) are compared as commercial-stage biopharmaceutical companies focused on pulmonary hypertension treatments. LQDA shows impressive commercial momentum with Yutrepia generating $170.4M in Q2 sales and achieving four consecutive profitable quarters, but faces heavy reliance on a single product. INSM offers a more diversified portfolio with Brinsupri's strong launch ($1.25-$1.40B 2026 guidance) and established Arikayce revenue, plus a broader pipeline. While LQDA has outperformed INSM significantly this year (106.9% vs -28.5%), analysts recommend INSM as the more compelling long-term choice due to its diversified revenue base and sustainable growth story.Zacks Investment Research · Aug 27, 2026

Stanley Druckenmiller's Portfolio Skips Megacap Tech Almost Entirely. Here's What He's Buying Instead.Billionaire investor Stanley Druckenmiller has dramatically reduced his exposure to megacap tech stocks, holding only Amazon as a minor position (0.32%) among the Magnificent Seven and completely exiting Alphabet. Instead, he's concentrating his $3 billion portfolio in biotech (Natera at 21%), semiconductors (Taiwan Semiconductor at 5.7%), and emerging markets, while adding positions in semiconductor suppliers like Broadcom, Micron, and STMicroelectronics.The Motley Fool · Aug 8, 2026

Nasdaq-100 Index® June 2026 Quarterly ChangesNasdaq announced the results of its June 2026 quarterly rebalance of the Nasdaq-100 Index, effective June 22, 2026. Five companies were added to the index: Astera Labs, CoreWeave, Nebius Group, Rocket Lab, and Teradyne. Five companies were removed: Charter Communications, Cognizant Technology Solutions, Insmed, Verisk Analytics, and Zscaler.GlobeNewswire Inc. · Jun 12, 2026

Nasdaq 100 Climbs Records, Oil Extends Drop As Iran Weighs Hormuz Deal: Stock Market TodayU.S. tech stocks reached record highs on May 7, 2026, as crude oil tumbled nearly 3% on hopes Iran will accept a U.S. memorandum to reopen the Strait of Hormuz. The Nasdaq 100 gained 0.4% to 28,706 while the S&P 500 rose 0.2% to 7,376. Earnings drove significant stock-specific moves, with major winners including AAON (+36%), Datadog (+30%), and H&R Block (+26%), while notable losers included Planet Fitness (-33%), Insmed (-22%), and Zoetis (-22%).Benzinga · May 7, 2026

to start trading

IN

INSMInsmed, Inc.

INSM

Pay with—

Available Balance0.00

Your PositionYou don't own any INSM yet.

Related Tickers

Earnings